Denosumab Injection for Osteoporosis and Bone Loss Conditions

Denosumab is a monoclonal antibody administered as a subcutaneous injection primarily for treating osteoporosis and increasing bone mass in various patient populations at high risk for fractures. It works by inhibiting a protein involved in bone breakdown, thereby improving bone strength. The medicine is given every six months and requires monitoring for calcium levels and other potential risks.

Denosumab is approved for:

• Treating postmenopausal women with osteoporosis at high fracture risk, including those with prior fractures or intolerant of other osteoporosis therapies.
• Increasing bone mass in men with osteoporosis at high fracture risk.
• Treating glucocorticoid-induced osteoporosis in men and women on systemic glucocorticoids (≥7.5 mg prednisone daily) expected to continue for at least 6 months.
• Increasing bone mass in men at high fracture risk receiving androgen deprivation therapy for nonmetastatic prostate cancer.
• Increasing bone mass in women at high fracture risk receiving adjuvant aromatase inhibitor therapy for breast cancer.

Denosumab-bbdz

Denosumab is a human monoclonal antibody that targets and inhibits RANK ligand (RANKL), a molecule essential for the formation, function, and survival of osteoclasts, the cells that break down bone. By blocking RANKL, denosumab decreases bone resorption, resulting in increased bone mass and strength.

General dosing

Administer 60 mg of denosumab as a subcutaneous injection once every 6 months.

Injection sites include the upper arm, upper thigh, or abdomen.

All patients should receive daily supplementation with 1000 mg calcium and at least 400 IU vitamin D.

Special considerations

• Pregnancy must be ruled out before administration in females of reproductive potential.
• In patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m2), evaluate for chronic kidney disease-mineral and bone disorder (CKD-MBD) before treatment initiation with laboratory tests including intact parathyroid hormone, serum calcium, 25(OH) vitamin D, and 1,25(OH)2 vitamin D.
• Monitor serum calcium weekly for the first month, then monthly afterward in patients with advanced CKD.
• If a dose is missed, administer as soon as possible and resume 6-month interval dosing from that date.

• Hypocalcemia not corrected before treatment
• Pregnancy
• Known hypersensitivity to denosumab or any component of the product

Severe hypocalcemia risk

Denosumab can cause severe, potentially life-threatening hypocalcemia, especially in patients with advanced chronic kidney disease or mineral and bone disorders. Correct pre-existing hypocalcemia before initiating treatment. Supplement adequately with calcium and vitamin D. Monitoring is essential.

Hypersensitivity

Anaphylaxis and other serious allergic reactions have been reported. Discontinue permanently if such reactions occur.

Osteonecrosis of the jaw (ONJ)

ONJ has been reported, typically associated with dental procedures or infections. Dental examination and preventive care recommended before starting therapy; maintain good oral hygiene during treatment.

Atypical femoral fractures

Rare atypical femoral fractures have been reported, often preceded by thigh or groin pain. Evaluate patients presenting with these symptoms.

Multiple vertebral fractures after discontinuation

Risk of multiple vertebral fractures increases after stopping denosumab. Transition patients to an alternative antiresorptive therapy.

Infections

Increased risk of serious infections including cellulitis. Patients with compromised immune systems should be closely monitored.

Dermatologic reactions

Includes dermatitis, eczema, and rash; discontinue treatment if severe.

Severe musculoskeletal pain

Discontinue if severe bone, joint, or muscle pain develops.

Common adverse reactions

• Back pain
• Pain in extremity
• Musculoskeletal pain
• Hypercholesterolemia
• Cystitis
• Arthralgia
• Nasopharyngitis
• Hypertension
• Bronchitis
• Headache

Serious adverse reactions

• Severe hypocalcemia requiring hospitalization
• Hypersensitivity reactions including anaphylaxis
• Osteonecrosis of the jaw
• Atypical femoral fractures
• Multiple vertebral fractures following discontinuation
• Serious infections including skin infections
• Dermatologic events such as dermatitis, eczema, and rash
• Pancreatitis (rare)

Concomitant use with other denosumab products is contraindicated. Use caution when combining denosumab with calcimimetic drugs, as they may increase hypocalcemia risk. Monitor mineral metabolism parameters closely.

Pregnancy

Use is contraindicated during pregnancy due to potential fetal harm. Pregnancy testing is required prior to administration in females of reproductive potential.

Lactation

Information on use during breastfeeding is limited.

No specific overdose information is provided. Monitor calcium levels closely in case of overdose.

Store refrigerated. Before administration, the prefilled syringe may be brought to room temperature (up to 25°C or 77°F) for 15 to 30 minutes. Do not warm by other means. Inspect visually for discoloration or particulate matter; do not use if solution is cloudy or contains particles.